NICE Nixes Therapy Utilized to Treat Hodgkin’s Lymphoma

The UK’s drug pricing watchdog is recommending that the National Health Service not reimburse for Takeda’s lymphoma drug Adcetris.

In a pointed appraisal of the relapsed Hodgkin’s lymphoma treatment, the National Institute for Health and Care Excellence said the drug’s efficacy is “immature and limited,” and not a cost-effective use of NHS resources.

While NICE acknowledged that the drug is the only licensed medical treatment for the condition, it asserted that there simply is not enough evidence of Adcetris’ clinical and cost effectiveness to recommend reimbursement.